Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 8Terminated 6Completed 5Withdrawn 3Not yet recruiting 3Recruiting 2No longer available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Thymoma 1Thymic epithelial tumor 1Neoplasm, Residual 1Colorectal Neoplasms 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × AP 1903 reagent × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07598955 2026-05-20

SELECT-NK-THYM

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Thoracic

Thymic epithelial tumor, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡